LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться